Nitta Gelatin India Ltd
Nitta Gelatin India Ltd is primarily engaged in the manufacture and sale of ossein, gelatin and collagen peptide.[1]
- Market Cap ₹ 844 Cr.
- Current Price ₹ 930
- High / Low ₹ 1,184 / 697
- Stock P/E 10.6
- Book Value ₹ 311
- Dividend Yield 0.81 %
- ROCE 30.6 %
- ROE 27.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 73.1% CAGR over last 5 years
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
244 | 303 | 287 | 355 | 357 | 341 | 343 | 261 | 294 | 354 | 429 | 487 | 487 | |
223 | 263 | 277 | 329 | 318 | 304 | 316 | 243 | 268 | 314 | 378 | 397 | 377 | |
Operating Profit | 21 | 40 | 10 | 27 | 39 | 37 | 27 | 18 | 27 | 40 | 51 | 90 | 110 |
OPM % | 8% | 13% | 3% | 8% | 11% | 11% | 8% | 7% | 9% | 11% | 12% | 18% | 23% |
1 | 2 | 0 | 2 | 2 | 9 | 5 | 1 | 3 | 5 | 6 | 5 | 12 | |
Interest | 6 | 7 | 6 | 8 | 6 | 4 | 7 | 8 | 8 | 5 | 5 | 4 | 1 |
Depreciation | 9 | 10 | 11 | 10 | 9 | 10 | 14 | 14 | 15 | 15 | 14 | 13 | 14 |
Profit before tax | 7 | 26 | -7 | 10 | 26 | 32 | 11 | -4 | 7 | 24 | 38 | 78 | 107 |
Tax % | 22% | 40% | 32% | 49% | 37% | 36% | 65% | 28% | -15% | 26% | 29% | 25% | |
5 | 16 | -5 | 5 | 17 | 20 | 4 | -3 | 8 | 18 | 27 | 59 | 80 | |
EPS in Rs | 4.54 | 13.91 | -5.46 | 5.62 | 18.38 | 22.57 | 4.16 | -2.91 | 8.70 | 19.72 | 29.30 | 64.72 | 88.12 |
Dividend Payout % | 66% | 22% | 0% | 18% | 14% | 11% | 60% | -52% | 29% | 15% | 14% | 12% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 7% |
3 Years: | 18% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 73% |
3 Years: | 95% |
TTM: | 49% |
Stock Price CAGR | |
---|---|
10 Years: | 26% |
5 Years: | 50% |
3 Years: | 73% |
1 Year: | 12% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 13% |
3 Years: | 19% |
Last Year: | 28% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Reserves | 99 | 111 | 106 | 113 | 125 | 130 | 138 | 133 | 134 | 154 | 176 | 231 | 274 |
Preference Capital | 0 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | |
36 | 42 | 53 | 53 | 54 | 84 | 104 | 101 | 79 | 75 | 76 | 29 | 16 | |
36 | 41 | 42 | 40 | 61 | 48 | 55 | 51 | 53 | 49 | 55 | 57 | 54 | |
Total Liabilities | 180 | 202 | 210 | 214 | 249 | 271 | 305 | 295 | 276 | 287 | 316 | 326 | 354 |
69 | 68 | 82 | 77 | 80 | 77 | 110 | 126 | 116 | 108 | 102 | 109 | 108 | |
CWIP | 6 | 8 | 8 | 8 | 7 | 11 | 10 | 3 | 4 | 2 | 7 | 7 | 8 |
Investments | 8 | 32 | 32 | 32 | 45 | 27 | 4 | 4 | 4 | 4 | 4 | 5 | 5 |
96 | 93 | 88 | 96 | 117 | 157 | 181 | 161 | 151 | 172 | 202 | 206 | 233 | |
Total Assets | 180 | 202 | 210 | 214 | 249 | 271 | 305 | 295 | 276 | 287 | 316 | 326 | 354 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
20 | 16 | 23 | 17 | 29 | 11 | 26 | 28 | 33 | 15 | 13 | 78 | |
-18 | -11 | -24 | -8 | -22 | -3 | -7 | -13 | -7 | -3 | -11 | -15 | |
-1 | -4 | 0 | -8 | 11 | -6 | -20 | -14 | -29 | -12 | -2 | -53 | |
Net Cash Flow | 0 | -0 | -0 | 1 | 18 | 2 | -0 | 1 | -3 | -0 | -1 | 10 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 26 | 31 | 28 | 23 | 21 | 56 | 65 | 74 | 34 | 57 | 65 | 59 |
Inventory Days | 119 | 138 | 129 | 99 | 112 | 127 | 151 | 202 | 220 | 161 | 148 | 133 |
Days Payable | 60 | 55 | 80 | 50 | 43 | 37 | 56 | 67 | 58 | 46 | 30 | 45 |
Cash Conversion Cycle | 86 | 114 | 77 | 72 | 90 | 147 | 160 | 210 | 196 | 172 | 182 | 148 |
Working Capital Days | 62 | 69 | 61 | 61 | 59 | 101 | 92 | 103 | 72 | 103 | 114 | 92 |
ROCE % | 9% | 22% | -1% | 11% | 17% | 17% | 7% | 2% | 6% | 13% | 17% | 31% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
-
Announcement under Regulation 30 (LODR)-Cessation
2d - Cessation of Director - Dr. Shinya Takahashi (DIN: 07809828) with effect from the close of business hours of 7th May 2024 consequent to expiry of …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
30 Apr - Copy of the press release issued by the Company in respect of Collagen Peptide Expansion Project.
- Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2024 And To Recommend Dividend, If Any. 29 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 25 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Portfolio
The company's product portfolio includes wellnex collagen peptides, gelatin, Di calcium phosphate, chitosan, and a few consumer products. [1] The products are used for pharmaceutical, agricultural, industrial, and food applications. [2]